about
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation.Somatic mutations in solid tumors: a spectrum at the service of diagnostic armamentarium or an indecipherable puzzle? The morphological eyes looking for BRAF and somatic molecular detections on cyto-histological samplesChemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin.Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosisCombined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivoTumour vascularization via endothelial differentiation of glioblastoma stem-like cells.Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.A BMP7 Variant Inhibits Tumor Angiogenesis In Vitro and In Vivo through Direct Modulation of Endothelial Cell Biology.The Role of CD56 in Thyroid Fine Needle Aspiration Cytology: A Pilot Study Performed on Liquid Based Cytology.Endothelial progenitor cell dysfunction in myelodysplastic syndromes: possible contribution of a defective vascular niche to myelodysplasia.Primary pancreatic lymphoma in a patient with maturity onset diabetes of the young type 3Circulating hematopoietic stem cells and putative intestinal stem cells in coeliac diseaseHuman cord blood endothelial progenitors promote post-ischemic angiogenesis in immunocompetent mouse model.miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal.KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients.Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome.A SPRY2 mutation leading to MAPK/ERK pathway inhibition is associated with an autosomal dominant form of IgA nephropathyCD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma.The role of fine-needle aspiration in the thyroid nodules of elderly patientsHypoxia-inducible factor-1α(Pro-582-Ser) polymorphism prevents iron deprivation in healthy blood donors.Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome.Advances in understanding the pathogenesis of familial thrombocythaemia.Cervical extramedullary lymphomatoid granulomatosis.The role of thyroid FNA cytology in pediatric malignant lesions: An overview of the literature.A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.Cytopathology of Follicular Cell Nodules.Impaired functional responses in follicular lymphoma CD8+TIM-3+ T lymphocytes following TCR engagement.The Immunohistochemical Analysis of SOCS3 Protein Identifies a Subgroup of Prostatic Cancer Biopsies With Aggressive Behavior.A BMP7 variant inhibits the tumorigenic potential of glioblastoma stem-like cells.The evaluation of miRNAs on thyroid FNAC: the promising role of miR-375 in follicular neoplasms.Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma.Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.Adult and cord blood endothelial progenitor cells have different gene expression profiles and immunogenic potential.Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: a cytohistologic institutional experience.Effect of antiviral therapy on pro-angiogenic hematopoietic and endothelial progenitor cells in HIV-infected people.Fanconi anemia gene variants in therapy-related myeloid neoplasms.Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma.Thrombopoietin receptor activation, thrombopoietin mimetic drugs, and hereditary thrombocytosis: remarks on bone marrow fibrosis.An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome.Small lymphocytic lymphoma in a patient with Fabry disease.
P50
Q27851655-58D9FD70-9FE6-4F36-AD14-D0EFE7C87D1BQ28070226-7CF65E15-DFB7-4243-9932-CC6C7B5FF6A1Q33274834-EC046FE2-152B-43FE-AF79-040665910007Q33587677-E141E953-DE86-463B-B11E-DF771B8C7890Q33720256-0F34EA42-8A8F-4A61-9DDC-6010B71915E8Q34151513-83BE1362-6B15-4C18-9468-8F7B9F1F723EQ34507964-04728598-D539-4F41-887D-4378864CB486Q35547649-A33F3843-3104-427A-A3DC-62F4FC289FB4Q35695232-DFC728CE-76D8-4603-B423-4AE04B106371Q35745087-356EBADD-2980-47F5-A7B5-8DBE2B3408B0Q35756495-4422F918-D854-434B-BCFB-1CBCE793D11AQ35838460-0E3F9E09-BC2C-438E-AF98-51F16E5D53A9Q35963703-3D7517DC-A6D0-4DBC-9E0A-DB9EB8B31087Q36545707-2C481346-8B79-4768-A615-1C356C467577Q36557853-94EAED69-5A08-4107-B07A-A0CF0938912CQ36560256-40624479-FBAF-40C6-BDBA-1CFB57681904Q36695721-450B53B5-49F8-42F1-9E7F-23694EFAE8A6Q36706850-088BF63A-6617-40EF-9CB2-9D520362F1CCQ37022024-51AC9281-471C-48A1-90B0-BD0DB57EB25DQ37306773-ACD26808-C7BF-435E-A2F0-4F14E0C3EE0AQ37706584-AC8486E9-533E-4975-A265-FB08218E5B3BQ37837958-338E3426-F602-4B0D-AE84-8614DEC0C1D2Q37864801-72FBA626-66DF-49EC-B03C-FFE7A87F2739Q38743798-3351775D-E489-41F1-A736-C885EE3ADB3EQ38828343-695A8A45-9748-406E-A529-6758844ED078Q39035880-7B0ABCC1-494E-4267-A2D7-7344A1F67BD6Q39090226-DED5FDF2-6F77-433B-8B94-2307F32C889AQ39227863-719C4B17-34E6-41F0-92B0-ECEB1A2F0AA0Q39357751-DEB2023E-16D1-48D4-A6D9-68704701FCC7Q40051337-3D6F93BC-98A0-4749-A729-E1AB43E963D1Q40956947-956D6DEB-5189-4F71-A82D-EA75BCD55BE0Q41526966-57636BBB-20EE-42FA-ADD2-8A50C1AE2F98Q41976922-04307B05-2898-41ED-9C6E-5DE2DC8A7667Q42230802-1BD8B5EF-B7A3-41D2-95CB-E2F90FA769CCQ42280057-49878769-84ED-4EE2-889F-D0F84D1966E9Q42421841-270156C1-935C-4385-AE01-579B5B466CABQ42952010-E8AFCBF0-B15B-487C-96BF-AEEDF667B8D8Q43048147-0EEB180C-1FCF-438C-888F-B089687A24DDQ43142221-2917441C-09CF-44C0-B133-2645B14CEBA0Q43530901-168F3DBB-B166-4610-BED9-A569BAE6BB9B
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Luigi Maria Larocca
@ast
Luigi Maria Larocca
@en
Luigi Maria Larocca
@es
Luigi Maria Larocca
@nl
Luigi Maria Larocca
@sl
type
label
Luigi Maria Larocca
@ast
Luigi Maria Larocca
@en
Luigi Maria Larocca
@es
Luigi Maria Larocca
@nl
Luigi Maria Larocca
@sl
altLabel
Gino
@en
prefLabel
Luigi Maria Larocca
@ast
Luigi Maria Larocca
@en
Luigi Maria Larocca
@es
Luigi Maria Larocca
@nl
Luigi Maria Larocca
@sl
P1053
A-1577-2008
P106
P1153
7006287805
P21
P31
P3829
P496
0000-0003-1739-4758